Compare drug alternatives
Kisqali® Alternatives
Kisqali®(ribociclib) | Verzenio®(abemaciclib) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
Up to $25. Learn more. | |
Annual Cap | |
$15,000. Learn more. | |
Assistance Expiration | |
Program may be rescinded, revoked, or amended by Novartis at any time. Learn more. | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common (incidence ≥ 20%) adverse reactions, including laboratory
abnormalities, are leukocytes decreased, neutrophils decreased, hemoglobin
decreased, lymphocytes decreased, aspartate aminotransferase increased,
gamma glutamyl transferase increased, alanine aminotransferase increased,
infections, nausea, creatinine increased, fatigue, platelets decreased, diarrhea,
vomiting, headache, constipation, alopecia, cough, rash, back pain, and
glucose serum decreased.. Learn more. | |
Mechanism of Actions (MoA) | |
Cytochrome P450 3A Inhibitor; Kinase Inhibitor . Learn more. | |
Special Populations | |
Is it safe to take KISQALI during pregnancy? No, KISQALI can cause fetal harm when administered to a pregnant woman based on findings from animal studies and the mechanism of action. The background risk of major birth defects and miscarriage for the indicated population is unknown. Pregnant women should be advised of the potential risk to a fetus. Can KISQALI be taken while breastfeeding? It is not known if ribociclib, the active ingredient in KISQALI, is present in human milk. Ribociclib and its metabolites readily passed into the milk of lactating rats. Lactating women are advised not to breastfeed while taking KISQALI and for at least 3 weeks after the last dose. Should females of reproductive potential take any precautions while taking KISQALI? Females of reproductive potential should undergo pregnancy testing prior to starting treatment with KISQALI. Effective contraception methods that result in less than 1% pregnancy rates are recommended during treatment with KISQALI and for at least 3 weeks after the last dose. Can KISQALI be used in pediatric patients? No, the safety and efficacy of KISQALI in pediatric patients has not been established. Can KISQALI be used in geriatric patients? No overall differences in safety or effectiveness of KISQALI were observed between geriatric patients (≥65 years old) and younger patients in clinical studies. Are there any dosage adjustments required for patients with hepatic impairment? No dose adjustment is necessary for patients with mild hepatic impairment (Child-Pugh class A). A reduced starting dose of 400 mg is recommended for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C). Are there any dosage adjustments required for patients with renal impairment? No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), a starting dose of 200 mg is recommended based on a renal impairment study in healthy subjects and non-cancer subjects. | |